Share Name Share Symbol Market Type Share ISIN Share Description
Tissue Regenix LSE:TRX London Ordinary Share GB00B5SGVL29 ORD 0.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 18.75p 18.00p 19.50p 18.75p 18.75p 18.75p 226.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.0 0.0 - 142.52

Tissue Regenix (TRX) Latest News

More Tissue Regenix News
Tissue Regenix Takeover Rumours

Tissue Regenix (TRX) Share Charts

1 Year Tissue Regenix Chart

1 Year Tissue Regenix Chart

1 Month Tissue Regenix Chart

1 Month Tissue Regenix Chart

Intraday Tissue Regenix Chart

Intraday Tissue Regenix Chart

Tissue Regenix (TRX) Discussions and Chat

Tissue Regenix Forums and Chat

Date Time Title Posts
13/2/201715:33Tissue Regenix delivering practical solutions to real clinical issues1,885.00
24/5/201609:30Third time lucky6,918.00
29/6/201320:26TOREX 2007 - THE TILLS RING AT LAST8.00
24/3/201312:45Torex - an insiders tale23.00
24/9/201209:10Torex Retailing8.00

Add a New Thread

Tissue Regenix (TRX) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
09:05:0519.0022642.94O
22/02/2017 14:46:0719.00657124.83O
22/02/2017 14:10:5418.2520036.50O
22/02/2017 12:48:2319.2565,00012,512.50O
22/02/2017 11:42:5018.1519,8483,602.41O
View all Tissue Regenix trades in real-time

Tissue Regenix (TRX) Top Chat Posts

DateSubject
23/2/2017
08:20
Tissue Regenix Daily Update: Tissue Regenix is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker TRX. The last closing price for Tissue Regenix was 18.75p.
Tissue Regenix has a 4 week average price of 19.69p and a 12 week average price of 19.81p.
The 1 year high share price is 22.50p while the 1 year low share price is currently 15p.
There are currently 760,124,264 shares in issue and the average daily traded volume is 77,860 shares. The market capitalisation of Tissue Regenix is Ā£142,523,299.50.
13/2/2017
15:33
channel pirate: Just been looking back through some of the company announcements over the last few months which re-assures me of my holding and maybe that on this dip, or subsequent dips, then it might be prudent to start adding again. From the announcement on 28th November : “The launch of OrthoPure™ XT remains on track for H1 2017, with CE mark approval in the same period. The first distribution agreements within Europe have been signed, indicators of the strong commercial and clinical support for OrthoPure™ XT, in preparation for rapid commercialisation in key European markets once approval is granted. Peter Hamer, Commercial Director TRX Orthopaedics Ltd: "We are extremely encouraged by the initial results returned from the study. Having entered our first distributor agreements, which highlight the demand and market opportunity for OrthoPure™ XT, we remain on track for launch of OrthoPure™ XT by the end of H1 2017.” So anytime in the next 4 months if all goes to plan, and that should see a significant rise in the share price if we are lucky ??
26/1/2017
11:52
channel pirate: With so many "sell" trades this month, the share price has been holding up very well. Does the market know good news that us pi's have not been made aware of yet ?. Maybe the U.S.A has been a better than expected source of revenue at this stage of things ? Maybe the company will be able to give us an update sometime soon.
15/11/2016
14:35
channel pirate: Would be nice if Mr Odell & Co announced something positive right now in order to reverse this falling share price.
02/8/2016
08:00
channel pirate: Igbert, It looks as though TRX may have called this wrong then this time with the Edison Report. O.K. I agree it reads well, but it looks to have caused a temporary negative reaction to the share price. I did add a few more yesterday at 18.35p and am quite happy to hold. Looks like Mr Woodford was still buying in the 19's !!
27/7/2016
06:08
multibagger: Hi Swiss Paul, Some very valid and searching questions. The biotech/healthcare product market is a very complex one due to various procurement and payment schemes/methods. In the UK, the NHS is a slow adopter and constrained by cost.The US is a much higher cost healthcare system and if TRX finds traction there, then there will be an uplift in share price. Though I keep an eye on TRX, I am not of the view that the share price will move upwards fast and not invested currently. I'm not a fan of either Odell or Samuels having met them both in Leeds at the AGM a few years ago, when I was the only shareholder present ! I'm not convinced about their their tech pipeline either, as regenerative medicine is moving a lot quicker than TRX are. I sold out not long after. My approach to biotech investing has changed and now largely go for funds....I hold AXA Framlington Biotech though I made good money from SCLP, SUMM and SAR in the past.Cyprotex (CRX) is moving in the right direction and their R&D product delivery and commercialisation is much more attractive - I pointed it out here when it was about 60p on this board - now about 135p. I hope TRX comes good for all holders - but my take is that investors may have a fairly long wait. Good luck all :)
30/6/2016
13:56
andrewbaker: Woodford has said he's still holding TRX and sold some for cash raising purposes, the directors have foregone an instant reward for a deferred one in the future, and only then if the share price performs, so they are supportive; and the company sells much outside of the UK, so is an exporter who will benefit from the fall in the UK currency. So, how come the price falls!? Maybe there's shorter term profit taking happening; but, as I'm a long term investor, that doesn't concern me so much: this business is a long term success story, in my view. Buying in now, or adding to an existing holding, has to be a profitable strategy for future profits, IMHO.
30/6/2016
07:13
bamboo2: Could be interim results from Meniscus trial as soon as next week. =========================================== 30 June 2016 Tissue Regenix Group plc Deferred Annual Bonus Scheme Leeds, 30 June 2016 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or "The Company") the regenerative medical devices company announces that an award has been made to Ian Jefferson, Chief Financial Officer and Antony Odell, Chief Executive Officer, pursuant to the terms of the Company's Deferred Annual Bonus Scheme. Under the terms of the Deferred Annual Bonus Scheme, Ian Jefferson waived his entitlement to receive 50% of his annual cash bonus in return for an option over 209,677 ordinary shares of 0.5p each in the Company and Antony Odell waived his entitlement to receive 36% of his annual cash bonus in return for an option over 255,484 ordinary shares of 0.5p each in the Company (the "Deferred Allocation"). The number of shares comprising the Deferred Allocation (i.e. subject to option) was calculated by dividing the amount of cash bonus waived by the closing market value of the ordinary shares of the Company on the dealing day immediately prior to the date of deferral. The Deferred Allocation option is not capable of exercise until the vesting date has been reached, which is three years from the date of the award. By participating in the Deferred Annual Bonus Scheme Ian Jefferson and Antony Odell are entitled to receive a matching award at no additional cost (the "Matching Allocation"), being an option over 629,031 and 766,452 ordinary 0.5p shares in the Company respectively. The Matching Allocation is not capable of exercise until the vesting date has been reached, which is three years from the date of award. Additionally, the Matching Allocation is not capable of exercise until the Company's share price has reached the following target prices and remained at those prices for at least 30 consecutive days: Performance criteria % Of Interest .Share Price To Vest ..........Criteria -------------- ------------ 33.33% .........20p -------------- ------------ 33.33%......... 25p -------------- ------------ 33.33%......... 30p -------------- ------------
31/5/2016
13:13
luminoso: Mmm, the quieter the board, the better the share price, it seems ! If it breaks 22p, can't see much holding us back til 30p. Edit - Doh ! Spoke too soon !
25/1/2016
08:34
igbertsponk: Hmm... paid for report signalling additional cash needed this year. Can't see the share price rising for a while with that hanging over it.
02/1/2014
12:50
multibagger: Hi BB2...my discussion and points of view are largely academic....market seems to be supportive of an upward trending TRX share price and I am certainly not complaining :) The market is what matters and decides the share price, not my opinion !
Tissue Regenix share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170223 09:41:38